OncRef
Skip to newsletter content
|
RCCJuly 2026
0:00 / 2:19
Renal Cell Carcinoma — Monthly Compass
Jul 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in renal cell carcinoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
renal cell carcinoma updates
Key Highlights
Key Highlights
  • Important Drug Publication Updates
    • Journal of Clinical Oncology published Phase 1 TRAVERSE results for ALLO‑316 (CD70‑targeting allogeneic CAR T) in advanced/metastatic RCC, reporting durable responses with a manageable safety profile and highlighting first durable remissions following allogeneic CAR T in a metastatic solid tumor.
  • Key Clinical Development Updates
    • Telix reported ongoing FDA consultations under Breakthrough Therapy for TLX250‑Px (89Zr‑girentuximab) with final CMC documentation nearing completion for a U.S. BLA resubmission expected shortly, while advancing companion therapeutic TLX250‑Tx and its broader RCC theranostics program.
  • Key Conference Updates
    • At KCRS 2026, investigators advanced a HIF‑2α–anchored strategy with casdatifan as a combination backbone—including a TKI‑sparing first‑line pairing with the PD‑1/VEGF bispecific ivonescimab—supported by ARC‑20 monotherapy tolerability and with initial combo data expected by mid‑2027 as PEAK‑1 evaluates casdatifan + cabozantinib in IO‑experienced disease.
    • KCRS 2026 also showcased modality diversification with TLX250‑Tx (177Lu‑girentuximab) entering the Phase 3 LUTEON trial for relapsed/recurrent ccRCC and FIT‑001 reporting ORR up to 50% and median PFS 13 months for darlifarnib + cabozantinib in cabozantinib‑naïve, pretreated ccRCC with safety consistent with individual agents.
  • Emerging Themes & Macro-Trends
    • Cross‑cutting momentum toward HIF‑2α–centric combinations, CAIX‑targeted radiotherapeutics, and off‑the‑shelf CD70 CAR T—demonstrating durable activity signals with manageable safety—is positioning programs for late‑phase testing and driving strategic investment in radiopharmacy and CD70 testing.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-07-01 and 2026-07-31 about renal cell carcinoma.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Allogene Therapeutics announced publication of Phase 1 TRAVERSE data for ALLO-316 (CD70-targeting AlloCAR T) in advanced/metastatic RCC, reporting durable responses with a manageable safety profile. The update reiterates prior FDA designations for this RCC program—Fast Track (March 2023) and Regenerative Medicine Advanced Therapy (RMAT; October 2024)—signaling continued FDA engagement on the development path. ¹ (read more)
  • Telix Pharmaceuticals’ Q2 2026 corporate update highlighted regulatory progress for TLX250-Px (Zircaix; 89Zr‑girentuximab) for kidney cancer imaging, noting ongoing FDA consultations under Breakthrough Therapy designation and that final CMC documentation is nearing completion for a U.S. BLA resubmission expected “shortly.” The company also referenced continued advancement of the companion therapeutic TLX250‑Tx and its broader RCC theranostics program. ² (read more)
Conference
Major Conference Updates
Conference Information
  • 2026 Kidney Cancer Research Summit (KCRS), InterContinental Boston, Boston, MA; July 23–24, 2026. (read more)
  • Overall sentiment: Momentum toward mechanism-driven combinations and new modalities in RCC—HIF-2α–anchored regimens, radiotherapeutics, and off‑the‑shelf cell therapy—showing durable activity signals with manageable safety, and positioning for late‑phase testing. (read more)
  • Theme 1: HIF-2α Backbone + PD-1/VEGF Bispecific Synergy
    • Significance: Clear push to establish HIF‑2α inhibition (casdatifan) as a combination backbone across lines, including a TKI‑sparing first‑line option when paired with ivonescimab (PD‑1/VEGF bispecific). (read more)
    • Mechanism insights / clinical impact: Casdatifan monotherapy in ARC‑20 showed promising activity and tolerability, supporting combinations; adding ivonescimab targets immune and angiogenic axes in one molecule and aims to prolong survival with potentially favorable tolerability. Initial combo data expected mid‑2027; PEAK‑1 is already evaluating casdatifan + cabozantinib in IO‑experienced disease. (read more)
    • Patient populations affected: First‑line metastatic ccRCC and IO‑experienced metastatic ccRCC cohorts (ARC‑20; PEAK‑1). (read more)
  • Theme 2: Radiotherapeutics (177Lu‑girentuximab) Advance to Phase 3
    • Significance: TLX250‑Tx (177Lu‑girentuximab tetraxetan) became the first radiopharmaceutical therapy to enter Phase 3 for ccRCC (LUTEON), signaling a credible new modality beyond ICI/TKI standards. (read more)
    • Mechanism insights / clinical impact: CAIX‑targeted radio‑antibody conjugate delivers tumor‑localized beta radiation; Phase 3 LUTEON (NCT07197580) is designed in relapsed/recurrent settings, with potential for durable disease control and theranostic integration if positive. (read more)
    • Patient populations affected: Relapsed or recurrent ccRCC after prior systemic therapy. (read more)
  • Theme 3: Off‑the‑Shelf CAR T Validates Activity in RCC
    • Significance: Allogeneic CAR T (ALLO‑316, CD70‑targeted) delivered first durable remissions in a solid tumor, supporting a scalable, faster‑to‑treat alternative to autologous approaches. (read more)
    • Mechanism insights / clinical impact: In TRAVERSE, the RP2 regimen achieved a 31% confirmed response rate in Stage IV RCC with high CD70 expression; safety was manageable with protocolized IEC‑HS management—expanding immunotherapy options for refractory disease. (read more)
    • Patient populations affected: Heavily pretreated Stage IV RCC, particularly CD70‑high tumors (TPS ≥50%). (read more)
  • Theme 4: Precision TKI Combinations to Overcome Resistance
    • Significance: Non‑IO, pathway‑complementary pairs (darlifarnib + cabozantinib) aim to improve outcomes post‑IO/TKI via selective mTORC1 blockade layered on VEGFR/MET/AXL inhibition. (read more)
    • Mechanism insights / clinical impact: FIT‑001 Phase 1a reported ORR up to 50% with median PFS 13 months in cabozantinib‑naïve, pretreated ccRCC; safety consistent with individual agents—supporting randomized expansion and dose selection for Phase 3. (read more)
    • Patient populations affected: Advanced ccRCC, post‑immunotherapy, cabozantinib‑naïve second/third‑line settings. (read more)
  • Significance
    • Expected clinical or translational readouts: Casdatifan + ivonescimab initial readout by mid‑2027; PEAK‑1 enrollment progressing; FIT‑001 randomized Phase 1b dose‑optimization ongoing; LUTEON Phase 3 activated. (read more)
    • Regulatory or policy implications: ALLO‑316 advancing under RMAT status; radiotherapeutics’ Phase 3 positioning could catalyze broader theranostic infrastructure in RCC. (read more)
    • Potential shifts in standard of care: Positive results could introduce HIF‑2α–centric doublets in first/early post‑IO lines, add CAIX‑targeted radiotherapy for relapsed disease, and create a biomarker‑driven niche for CD70‑high RCC. (read more)
    • Strategic implications: Prioritize PD‑1/VEGF bispecific alliances around HIF‑2α backbones; invest in radiopharmacy/CD70 testing to enable modality adoption; monitor FTI + TKI data as a non‑IO alternative for IO‑refractory patients. (read more)
Publications Related to Approved Drugs
Phase 3
pembrolizumab and berahyaluronidase alfa-pmph
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. The phase 3 LITESPARK-022 trial demonstrated that adding the HIF-2α inhibitor belzutifan to adjuvant pembrolizumab significantly improved disease-free survival for patients with resected clear-cell renal-cell carcinoma at high risk of recurrence. While this combination presents a promising new adjuvant strategy, it was associated with a greater risk of grade 3 or higher toxic effects compared to pembrolizumab monotherapy. () .
Phase 3
ipilimumab
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial. With a median follow-up of 9.3 years, the final analysis of the CheckMate 214 trial confirms the long-term, substantial survival benefit and durable responses of nivolumab plus ipilimumab over sunitinib in the first-line treatment of advanced renal cell carcinoma. This long-term data solidifies the combination's role as a standard of care, further supported by a lower incidence of grade 3-4 treatment-related adverse events compared to sunitinib. () .
New Publications Related to Drugs in Clinical Trial Development
Phase 2
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). This phase II trial investigated the addition of radium-223 to cabozantinib for patients with metastatic renal cell carcinoma (mRCC) and bone metastases. The study was concluded early for futility, as the combination did not improve symptomatic skeletal event-free survival compared to cabozantinib monotherapy, although the safety profile was deemed manageable. ()
Phase 2
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma. The OMNIVORE trial's long-term follow-up demonstrated that a response-adaptive strategy, where patients with an early objective response to nivolumab monotherapy could discontinue treatment, resulted in prolonged treatment-free survival for a meaningful subset of individuals. Conversely, the addition of salvage ipilimumab for non-responders showed limited efficacy, reinforcing the current standard of upfront dual checkpoint blockade. ()
N/A
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. This trial established the feasibility and safety of an intensive systolic blood pressure (SBP) control strategy (target <120 mm Hg) in patients with renal cell or thyroid cancer being treated with VEGFR tyrosine kinase inhibitors. The intensive approach successfully lowered SBP compared to usual care without increasing adverse events, supporting more proactive hypertension management in this patient population. ()
Phase 3
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. This analysis of the phase 3 ETER100 trial found that the combination of benmelstobart (anti-PD-L1) and anlotinib (TKI) did not increase the risk of renal injury compared to sunitinib in patients with advanced RCC. Importantly, the occurrence of renal function abnormalities during treatment was not associated with worse survival outcomes, confirming a manageable renal safety profile for the combination. ()
Phase 2
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. A pooled analysis of two phase 2 trials provides evidence that adding maintenance pembrolizumab to metastasis-directed therapy (MDT) improves clinical outcomes for patients with oligometastatic clear cell RCC. The combination was associated with a trend toward longer progression-free survival and favorable immunomodulatory changes, supporting the rationale for the ongoing randomized ASTROs trial. ()
Phase 4
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. The ITALIC-RCC is a phase 4 trial designed to clarify the role of local treatment for the primary tumor in the immunotherapy era. It will evaluate whether deferred cytoreductive nephrectomy or stereotactic body radiotherapy improves overall survival in mRCC patients who have already achieved a benefit from first-line anti-PD-1-based systemic therapy. ()
Phase 1
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer. The oral HIF-2α inhibitor casdatifan demonstrated significant and durable antitumor activity with a manageable safety profile in patients with refractory metastatic clear cell RCC. Data from the ARC-20 study established a clear link between on-target HIF-2α pathway modulation, as measured by serum erythropoietin levels, and clinical efficacy, including an overall objective response rate of 31%. ()
Phase 2
Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial. The phase IIa MITRIC trial confirmed that fecal microbiota transplantation (FMT) is safe and feasible in patients with advanced, ICI-refractory cancers, including renal cell carcinoma. However, the study reported limited clinical activity, with no objective responses observed, suggesting that further research is needed to identify appropriate patient populations and optimize donor selection for this strategy. ()
PHASE2, PHASE3
CT-guided intratumoral immunotherapy for advanced solid tumors: a prospective clinical study of safety and systemic antitumor effects. This prospective study showed that direct, CT-guided intratumoral injection of various immune checkpoint inhibitors is a safe delivery method for patients with advanced solid tumors, resulting in a low rate of high-grade systemic toxicities. While the objective response rate was modest (11.24%), the approach represents a promising strategy to potentially mitigate the adverse effects associated with standard intravenous immunotherapy. ()
Phase 1
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. The phase I TRAVERSE trial provides proof-of-concept for allogeneic CAR T-cell therapy in a solid tumor, demonstrating that ALLO-316, which targets CD70, has a manageable safety profile and encouraging antitumor activity in heavily pretreated ccRCC. The objective response rate was 31.3% in patients with high CD70 tumor expression, highlighting a potential new therapeutic avenue for this population. ()
Phase 2
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. Exploratory results from the SUNNIFORECAST trial suggest a potential survival benefit for first-line ipilimumab plus nivolumab over standard-of-care TKI monotherapy in patients with papillary renal cell carcinoma. This benefit in 12-month overall survival and median OS was particularly evident in patients whose tumors had a PD-L1 combined positive score (CPS) greater than 1. ()
PHASE1, PHASE2
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma. Translational analysis from the RAPPORT trial identified predictive biomarkers for response to stereotactic ablative body radiotherapy (SABR) combined with pembrolizumab in oligometastatic ccRCC. Responders exhibited greater pre-treatment cytotoxic T-cell infiltration and a distinct post-treatment proliferative burst of activated CD8+ T-cells, linking the trafficking of pre-existing tumor-enriched T-cell clones to clinical benefit. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in renal cell carcinoma updated from 2026-07-01 to 2026-07-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting1-5-1-7
Recruiting1499-1134
Available-------
Approved for Marketing-------
Active, Not Recruiting7413-3-27
Completed-------
Total221327-5168
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Cabozantinib S-malate, : Atezolizumab, Nab-paclitaxel NCT05092373 RECRUITING Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax 2026-09-01
Belzutifan NCT02974738 ACTIVE_NOT_RECRUITING A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors 2026-09-08
Tacrolimus, Prednisone, : Ipilimumab, : Nivolumab NCT03816332 ACTIVE_NOT_RECRUITING Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers 2026-09-19
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Cabozantinib S-malate NCT04071223 ACTIVE_NOT_RECRUITING A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal) 2026-10-01
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
No phase 3 trials completing within the next three months.
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.